IL-15/IL-15Rα-targeted CRISPRa boosts NK cell effector function against HIV-infected cells
Journal of Leukocyte Biology · 05.11.2026
DOI: 10.1093/jleuko/qiag140 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Leukocyte Biology, online erschienen am 05.11.2026. Verfasst von Samuel Brancazio und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Neurovirology and Gene Editing, Department of Microbiology, Immunology and Inflammation, Lewis Katz School of Medicine, Temple University,…. Hauptthemen laut MEDLINE: Killer Cells, Natural, Interleukin-15, HIV Infections, Interleukin-15 Receptor alpha Subunit. Gefördert von: Cure Collaboratory, National Institute of Allergy and Infectious Diseases, US.
Abstract (Originalsprache)
Like many other immune cell types, natural killer (NK) cells exhibit impaired functionality in people with HIV (PWH), limiting their ability to efficiently target and eliminate HIV-infected cells and contributing to the persistence of the HIV reservoir. Recently, adoptive NK cell therapy using activated or engineered NK cells has emerged as a promising immunotherapeutic strategy for cancer; however, its application to HIV remains in the early stages of development. NK cells primarily rely on interleukin-15 (IL-15) signaling for their development, survival, and maintenance, and dysregulated IL-15 signaling has been reported in PWH. We hypothesized that simultaneous enhancement of IL-15 and IL-15 receptor alpha (IL-15Rα) expression would improve NK cell effector function and promote clearance of HIV reservoir. Utilizing dCas9-VPR-mediated multiplex CRISPR activation (CRISPRa), we successfully upregulated both IL-15 and IL-15Rα expression in the same primary NK cells without altering the genomic sequence. CRISPRa-treated NK cells displayed increased IL-15 and IL-15Rα transcript levels, as measured by RT-qPCR and significantly elevated surface expression of IL-15Rα, as determined by flow cytometry. Enhanced IL-15/IL-15Rα expression increased NK cell metabolic activity and cytotoxicity against target K562 cells, a chronic myelogenous leukemia cell line, indicating improved effector function. Furthermore, in co-culture experiments using an HIV-positive T-cell line, IL-15/IL-15Rα-CRISPRa-treated NK cells demonstrated enhanced target cell elimination and increased secretion of IFN-γ. Together, these findings provide a proof of concept that multiplex CRISPRa can be used to enhance NK cell function, representing a novel strategy to improve persistence and therapeutic efficacy in HIV and other disease settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Neurovirology and Gene Editing, Department of Microbiology, Immunology and Inflammation, Lewis Katz School of Medicine, Temple University, 3500 N Broad Street, Philadelphia, PA 19140, United States.
- Department of Medicine, Rutgers Institute for Translational Medicine and Science, Rutgers, The State University of New Jersey, 89 French Street, New Brunswick, NJ 08901, United States.
- Institute of Human Immunology, Shenzhen Medical Academy of Research and Translation, 17F, Tower A, Guangming Life Science Park, Shenzhen, Guangdong, China.
ORCID-Profile: Samuel Brancazio, Tricia H Burdo, Liang Shan, Rafal Kaminski
Förderung
- Cure Collaboratory
- National Institute of Allergy and Infectious Diseases
- US
- NIMH NIH HHS
Zitieren
APA
Brancazio, S., Burdo, T. H., Shan, L., & Kaminski, R. (2026). IL-15/IL-15Rα-targeted CRISPRa boosts NK cell effector function against HIV-infected cells. Journal of Leukocyte Biology. https://doi.org/10.1093/jleuko/qiag140
Vancouver
Brancazio S, Burdo TH, Shan L, Kaminski R. IL-15/IL-15Rα-targeted CRISPRa boosts NK cell effector function against HIV-infected cells. Journal of Leukocyte Biology. 2026. doi:10.1093/jleuko/qiag140
BibTeX
@article{Brancazio2026,
author = {Brancazio, Samuel and Burdo, Tricia H and Shan, Liang and Kaminski, Rafal},
title = {IL-15/IL-15Rα-targeted CRISPRa boosts NK cell effector function against HIV-infected cells},
journal = {Journal of Leukocyte Biology},
year = {2026},
doi = {10.1093/jleuko/qiag140}
}
EUVIMED